JUNSHI BIO(01877),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

01877 JUNSHI BIO

Closed Hong Kong Special Administrative Region Establishment Day 06-28 16:08:42

11.700

-0.060

-0.51%

High11.800	Low11.500	Vol635.74K
Open11.680	D1 Closing11.760	Amplitude2.55%
Mkt Cap11.53B	Tradable Cap2.57B	Total Shares985.69M
T/O7.41M	T/O Rate0.29%	Tradable Shares219.30M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Disclaimer: HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the information provided, but do not guarantee its absolute accuracy and reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.

{"stockData":{"symbol":"01877","market":"HK","secType":"STK","nameCN":"JUNSHI BIO","latestPrice":11.7,"timestamp":1719562122030,"preClose":11.76,"halted":0,"volume":635742,"delay":0,"floatShares":219295700,"shares":985689871,"eps":-2.481640903871839,"marketStatus":"Closed Hong Kong Special Administrative Region Establishment Day","change":-0.06,"latestTime":"06-28 16:08:42","open":11.68,"high":11.8,"low":11.5,"amount":7414840,"amplitude":0.02551,"askPrice":11.72,"askSize":800,"bidPrice":11.7,"bidSize":42800,"shortable":3,"etf":0,"ttmEps":-2.2054096687964257,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1719883800000},"marketStatusCode":7,"adr":0,"listingDate":1545580800000,"exchange":"SEHK","adjPreClose":11.76,"openAndCloseTimeList":[[1719538200000,1719547200000],[1719550800000,1719561600000]],"volumeRatio":0.9469608840341737,"lotSize":200,"spreadScale":0,"tradeCurrency":"HKD","astockBrief":{"symbol":"688180","market":"SH","secType":"STK","nameCN":"Shanghai Junshi Biosciences Co., Ltd.","latestPrice":27.98,"timestamp":1719804585000,"preClose":29.05,"halted":0,"volume":2231400,"delay":0,"premium":"-60.91"}},"requestUrl":"/m/hq/s/01877","defaultTab":"news","newsList":[{"id":"2446735697","title":"Shanghai Junshi Biosciences Breast Cancer Drug Obtains DRC from NMPA; Shares Jump 8%","url":"https://stock-news.laohu8.com/highlight/detail?id=2446735697","media":"MT Newswires Live","labels":[],"top":-1,"share":"https://ttm.financial/m/news/2446735697?lang=en_us&edition=fundamental","pubTime":"2024-06-26 16:31","pubTimestamp":1719390684,"startTime":"0","endTime":"0","summary":"Shanghai Junshi Biosciences  said China's National Medical Products Administration  issued a Drug Registration Certificate for toripalimab, the company's new drug for breast cancer treatment, according to a Tuesday filing on the Hong Kong bourse.Toripalimab, which goes by the trade name of TUOYI, in combination with paclitaxel for injection  is meant to be the first-line treatment of recurrent or metastatic triple-negative breast cancer.The pharmaceutical company's shares rose 8% recently.Price : $12.00, Change: $+0.92, Percent Change: +8.30%","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK1583","BK1515","BK4023","BK1161","01877","BK4526","BK4585","HKD","BK4588"],"gpt_icon":0},{"id":"2446984411","title":"BRIEF-Shanghai Junshi Biosciences Says Approval Of Supplemental New Drug Application For Toripalimab By China's NMPA","url":"https://stock-news.laohu8.com/highlight/detail?id=2446984411","media":"Reuters","labels":[],"top":-1,"share":"https://ttm.financial/m/news/2446984411?lang=en_us&edition=fundamental","pubTime":"2024-06-25 22:09","pubTimestamp":1719324571,"startTime":"0","endTime":"0","summary":"June 25 (Reuters) - Shanghai Junshi Biosciences Co Ltd :   * APPROVAL OF SUPPLEMENTAL NEW DRUG APPLICATION FOR TORIPALIMAB BY CHINA'S NMPA Further company coverage:    ((Reuters.Briefs@thomsonreuters.com;))","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","01877","BK1583","BK1515"],"gpt_icon":0},{"id":"2443291675","title":"Junshi Biosciences' Cancer Drug Gets Registration Certificate from Chinese Regulator","url":"https://stock-news.laohu8.com/highlight/detail?id=2443291675","media":"MT Newswires Live","labels":[],"top":-1,"share":"https://ttm.financial/m/news/2443291675?lang=en_us&edition=fundamental","pubTime":"2024-06-13 13:44","pubTimestamp":1718257477,"startTime":"0","endTime":"0","summary":"Shanghai Junshi Biosciences  said Chinas National Medical Products Administration issued the drug registration certificate for Toripalimab Injection, its extensive-stage small cell lung cancer, according to a Wednesday filing on the Hong Kong bourse. Toripalimab Injection, in combination with Etoposide plus platinum, is used as the first-line treatment for extensive-stage small-cell lung cancer. Price : $12.34, Change: $+0.10, Percent Change: +0.82%","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK0239","BK4023","HKD","01877","BK1583","BK4585","BK4526","BK1515","688180","BK4588","BK1161"],"gpt_icon":0},{"id":"2442584221","title":"Junshi Bio Achieves Primary Endpoints in Phase 3 Trial of Liver Cancer Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=2442584221","media":"MT Newswires Live","labels":[],"top":-1,"share":"https://ttm.financial/m/news/2442584221?lang=en_us&edition=fundamental","pubTime":"2024-06-12 16:30","pubTimestamp":1718181042,"startTime":"0","endTime":"0","summary":"Shanghai Junshi Biosciences  achieved the primary endpoints of a phase 3 trial for its toripalimab advanced liver cancer treatment, according to a Wednesday filing with the Shanghai Stock Exchange.The drug showed progression-free survival and overall survival during the trial, the filing said. Junshi Bio will submit a marketing application for the drug soon, it said.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK1583","BK1515","688180","BK1161","BK0239","01877"],"gpt_icon":0},{"id":"2442029302","title":"Shanghai Junshi Biosciences Cancer Drug Shows Positive Phase III Trial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2442029302","media":"MT Newswires Live","labels":[],"top":-1,"share":"https://ttm.financial/m/news/2442029302?lang=en_us&edition=fundamental","pubTime":"2024-06-12 14:14","pubTimestamp":1718172888,"startTime":"0","endTime":"0","summary":"Shanghai Junshi Biosciences  announced positive results from a Phase III clinical trial testing its drug toripalimab in combination with bevacizumab for advanced hepatocellular carcinoma , a type of liver cancer, according to a Tuesday filing on the Hong Kong bourse.  Toripalimab, along with bevacizumab, is being evaluated as a potential first-line treatment for this aggressive form of cancer.Junshi Biosciences plans to submit a supplemental new drug application to regulatory authorities based on these trial results.Junshi's shares were up over 1% in recent trading. Price : $12.36, Change: $+0.18, Percent Change: +1.48%","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK1583","BK4134","HKD","III","BK4526","BK4023","BK1515","01877","HCC","BK4588","BK1161","BK4006","BK4585"],"gpt_icon":0},{"id":"2440711801","title":"retail investors who own 51% along with institutions invested in Shanghai Junshi Biosciences Co., Ltd. (HKG:1877) saw increase in their holdings value last week","url":"https://stock-news.laohu8.com/highlight/detail?id=2440711801","media":"Simply Wall St.","labels":[],"top":-1,"share":"https://ttm.financial/m/news/2440711801?lang=en_us&edition=fundamental","pubTime":"2024-06-02 08:10","pubTimestamp":1717287034,"startTime":"0","endTime":"0","summary":"Key Insights Shanghai Junshi Biosciences' significant retail investors ownership suggests that the key decisions are...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-1877/shanghai-junshi-biosciences-shares/news/retail-investors-who-own-51-along-with-institutions-invested-3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK1515","BK1161","BK1583","01877"],"gpt_icon":0},{"id":"2433449547","title":"Shanghai Junshi Biosciences Co., Ltd. (HKG:1877) Shares Fly 27% But Investors Aren't Buying For Growth","url":"https://stock-news.laohu8.com/highlight/detail?id=2433449547","media":"Simply Wall St.","labels":[],"top":-1,"share":"https://ttm.financial/m/news/2433449547?lang=en_us&edition=fundamental","pubTime":"2024-05-06 08:42","pubTimestamp":1714956142,"startTime":"0","endTime":"0","summary":"Shanghai Junshi Biosciences Co., Ltd. ( HKG:1877 ) shareholders would be excited to see that the share price has had a...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-1877/shanghai-junshi-biosciences-shares/news/shanghai-junshi-biosciences-co-ltd-hkg1877-shares-fly-27-but","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["ISBC","BK1161","01877","BK1515","BK4211","BK1583"],"gpt_icon":0},{"id":"2432569729","title":"Investors in Shanghai Junshi Biosciences (HKG:1877) from three years ago are still down 86%, even after 22% gain this past week","url":"https://stock-news.laohu8.com/highlight/detail?id=2432569729","media":"Simply Wall St.","labels":[],"top":-1,"share":"https://ttm.financial/m/news/2432569729?lang=en_us&edition=fundamental","pubTime":"2024-05-01 07:47","pubTimestamp":1714520861,"startTime":"0","endTime":"0","summary":"This week we saw the Shanghai Junshi Biosciences Co., Ltd. ( HKG:1877 ) share price climb by 22%. But that is meagre...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-1877/shanghai-junshi-biosciences-shares/news/investors-in-shanghai-junshi-biosciences-hkg1877-from-three-1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK1161","BK4211","BK1583","ISBC","BK1515","01877"],"gpt_icon":0},{"id":"2429542744","title":"BRIEF-Shanghai Junshi Biosciences Says Drug Office In Hong Kong Accepted New Drug Application Of Toripalimab","url":"https://stock-news.laohu8.com/highlight/detail?id=2429542744","media":"Reuters","labels":[],"top":-1,"share":"https://ttm.financial/m/news/2429542744?lang=en_us&edition=fundamental","pubTime":"2024-04-24 22:27","pubTimestamp":1713968858,"startTime":"0","endTime":"0","summary":"April 24 (Reuters) - Shanghai Junshi Biosciences Co Ltd :   * DRUG OFFICE IN HONG KONG ACCEPTED NEW DRUG APPLICATION OF TORIPALIMABFurther company coverage:    ((Reuters.Briefs@thomsonreuters.com;))","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1583","01877","BK1515","BK1161"],"gpt_icon":0},{"id":"2424459610","title":"BRIEF-Shanghai Junshi Biosciences Says Acceptance Of Supplemental New Drug Applications By NMPA","url":"https://stock-news.laohu8.com/highlight/detail?id=2424459610","media":"Reuters","labels":[],"top":-1,"share":"https://ttm.financial/m/news/2424459610?lang=en_us&edition=fundamental","pubTime":"2024-04-02 21:49","pubTimestamp":1712065749,"startTime":"0","endTime":"0","summary":"April 2 (Reuters) - Shanghai Junshi Biosciences Co Ltd :   * ACCEPTANCE OF SUPPLEMENTAL NEW DRUG APPLICATIONS FOR ONGERICIMAB INJECTION BY NMPA Further company coverage:    ((Reuters.Briefs@thomsonreuters.com;))","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","01877","BK1583","BK1515"],"gpt_icon":0},{"id":"2423598483","title":"Press Release: Junshi Biosciences Announces 2023 Full Year Financial Results and Provides Corporate Updates","url":"https://stock-news.laohu8.com/highlight/detail?id=2423598483","media":"Dow Jones","labels":[],"top":-1,"share":"https://ttm.financial/m/news/2423598483?lang=en_us&edition=fundamental","pubTime":"2024-03-29 12:24","pubTimestamp":1711686240,"startTime":"0","endTime":"0","summary":"SHANGHAI, China, March 29, 2024  -- Shanghai Junshi Biosciences Co., Ltd , a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, announced its financial results for the full year of 2023 and provided corporate updates.-- Total revenue was approximately RMB1,503 million during 2023. The revenue. from pharmaceutical products increased by approximately 58% compared to. 2022. The sales revenue of TUOYI  was approximately. RMB919 million, representing an increase of approximately 25% compared to. -- Total research and development  expenses were approximately. RMB1,937 million in 2023, representing a decrease of approximately 19%. compared to 2022. The decrease in R&D expenses was mainly due to the. strategic management of R&D investments in certain early-stage pipelines,while optimizing resource allocation and focusing on R&D pipelines with. During 2023, we continued to focus on \"unmet medical needs\" and have","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1515","BK4232","BK4022","03160","BK4585","BK1161","BK4099","01877","BK4555","TM","R","BK1583","BK4588"],"gpt_icon":0},{"id":"2421323898","title":"Is Shanghai Junshi Biosciences (HKG:1877) Using Debt Sensibly?","url":"https://stock-news.laohu8.com/highlight/detail?id=2421323898","media":"Simply Wall St.","labels":[],"top":-1,"share":"https://ttm.financial/m/news/2421323898?lang=en_us&edition=fundamental","pubTime":"2024-03-22 15:23","pubTimestamp":1711092227,"startTime":"0","endTime":"0","summary":"Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-1877/shanghai-junshi-biosciences-shares/news/is-shanghai-junshi-biosciences-hkg1877-using-debt-sensibly","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK1515","BK1161","01877","BK1583"],"gpt_icon":0},{"id":"2413522792","title":"Individual investors who hold 47% of Shanghai Junshi Biosciences Co., Ltd. (HKG:1877) gained 8.2%, insiders profited as well","url":"https://stock-news.laohu8.com/highlight/detail?id=2413522792","media":"Simply Wall St.","labels":[],"top":-1,"share":"https://ttm.financial/m/news/2413522792?lang=en_us&edition=fundamental","pubTime":"2024-02-22 12:56","pubTimestamp":1708577760,"startTime":"0","endTime":"0","summary":"Key Insights The considerable ownership by individual investors in Shanghai Junshi Biosciences indicates that they...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-1877/shanghai-junshi-biosciences-shares/news/individual-investors-who-hold-47-of-shanghai-junshi-bioscien","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK1515","BK1161","01877","BK1583"],"gpt_icon":0},{"id":"2406754728","title":"Risks Still Elevated At These Prices As Shanghai Junshi Biosciences Co., Ltd. (HKG:1877) Shares Dive 29%","url":"https://stock-news.laohu8.com/highlight/detail?id=2406754728","media":"Simply Wall St.","labels":[],"top":-1,"share":"https://ttm.financial/m/news/2406754728?lang=en_us&edition=fundamental","pubTime":"2024-01-27 06:40","pubTimestamp":1706308807,"startTime":"0","endTime":"0","summary":"Shanghai Junshi Biosciences Co., Ltd. ( HKG:1877 ) shareholders that were waiting for something to happen have been...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-1877/shanghai-junshi-biosciences-shares/news/risks-still-elevated-at-these-prices-as-shanghai-junshi-bios","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK1161","01877","BK1583","BK1515"],"gpt_icon":0},{"id":"2401865688","title":"Further weakness as Shanghai Junshi Biosciences (HKG:1877) drops 7.6% this week, taking three-year losses to 69%","url":"https://stock-news.laohu8.com/highlight/detail?id=2401865688","media":"Simply Wall St.","labels":[],"top":-1,"share":"https://ttm.financial/m/news/2401865688?lang=en_us&edition=fundamental","pubTime":"2024-01-07 09:14","pubTimestamp":1704590067,"startTime":"0","endTime":"0","summary":"While not a mind-blowing move, it is good to see that the Shanghai Junshi Biosciences Co., Ltd. ( HKG:1877 ) share...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-1877/shanghai-junshi-biosciences-shares/news/further-weakness-as-shanghai-junshi-biosciences-hkg1877-drop","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK1583","01877","BK1515","BK1161"],"gpt_icon":0}],"profile":{"stockEarnings":[{"period":"1week","weight":0.0372},{"period":"1month","weight":0.0541},{"period":"3month","weight":0.1854},{"period":"6month","weight":-0.3981},{"period":"1year","weight":-0.48},{"period":"ytd","weight":-0.3981}],"compareEarnings":[{"period":"1week","weight":-0.0172},{"period":"1month","weight":-0.041},{"period":"3month","weight":0.0712},{"period":"6month","weight":0.0394},{"period":"1year","weight":-0.0642},{"period":"ytd","weight":0.0394}],"compareStock":{"symbol":"HSI","name":"HSI"},"description":"Shanghai Junshi Biosciences Co Ltd is a China-based company mainly engaged in innovation-driven biopharmaceutical business. The Company develops innovative drugs and provides clinical research commercialization services worldwide. The Company mainly provides its products in the treatment of tumor immunotherapy, metabolic diseases, inflammation or autoimmune diseases, as well as nervous system diseases. The Company's products are mainly used to treat melanoma, nasopharyngeal cancer, esophageal cancer, urothelial cancer, malignant lymphoma and others. The Company provides its products for domestic and overseas markets.","yearOnYearQuotes":[{"month":1,"riseRate":0.166667,"avgChangeRate":-0.122873},{"month":2,"riseRate":0.833333,"avgChangeRate":0.02917},{"month":3,"riseRate":0.666667,"avgChangeRate":0.049114},{"month":4,"riseRate":0.833333,"avgChangeRate":0.112597},{"month":5,"riseRate":0.333333,"avgChangeRate":-0.034116},{"month":6,"riseRate":0.333333,"avgChangeRate":-0.02585},{"month":7,"riseRate":0.4,"avgChangeRate":-0.076121},{"month":8,"riseRate":0,"avgChangeRate":-0.093613},{"month":9,"riseRate":0,"avgChangeRate":-0.097134},{"month":10,"riseRate":0.4,"avgChangeRate":0.053036},{"month":11,"riseRate":0.6,"avgChangeRate":0.067975},{"month":12,"riseRate":0.8,"avgChangeRate":0.175695}],"exchange":"SEHK","name":"JUNSHI BIO","nameEN":"JUNSHI BIO"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.24.2","shortVersion":"4.24.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"JUNSHI BIO(01877),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest JUNSHI BIO(01877) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"JUNSHI BIO,01877,JUNSHI BIO股票,JUNSHI BIO股票老虎,JUNSHI BIO股票老虎国际,JUNSHI BIO行情,JUNSHI BIO股票行情,JUNSHI BIO股价,JUNSHI BIO股市,JUNSHI BIO股票价格,JUNSHI BIO股票交易,JUNSHI BIO股票购买,JUNSHI BIO股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"JUNSHI BIO(01877),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest JUNSHI BIO(01877) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}